Cytopoint Now Approved for Canine Allergic Dermatitis
The US Department of Agriculture has expanded the indication for Cytopoint (Zoetis) to include allergic dermatitis in dogs.
Zoetis announced today that its monoclonal antibody (mAb) therapeutic Cytopoint—initially approved in 2016 to treat canine atopic dermatitis—has been granted an extended license to treat allergic dermatitis.
Cytopoint works by mimicking the activity of natural antibodies to selectively bind and neutralize interleukin-31, a key protein involved in triggering pruritus in dogs, thus interrupting the itch cycle.
“Zoetis strives to advance the treatment of dogs with canine pruritus,” Andrew Hillier, BVSc, MANZCVS, DACVD, veterinary specialty operations and veterinary medical lead, dermatology for Zoetis, said. “We know that itch can erode cherished bonds and can take an emotional toll on owners. With this new Cytopoint indication for allergic dermatitis, veterinarians have another option to provide relief for their pruritic patients as they are going through the diagnostic process.”
Click here for more information on about Cytpoint.
